152 related articles for article (PubMed ID: 38738774)
1. Apremilast Decreased Proinflammatory Cytokines and Subsequently Increased Inhibitory ones in Psoriasis: A Prospective Cohort Study.
Fukasawa T; Yoshizaki-Ogawa A; Enomoto A; Sato S; Yoshizaki A
Acta Derm Venereol; 2024 May; 104():adv37555. PubMed ID: 38738774
[No Abstract] [Full Text] [Related]
2. Real-world, single-centre experience of apremilast for the treatment of moderate to severe psoriasis.
Wong TH; Sinclair S; Smith B; Fraser C; Morton CA
Clin Exp Dermatol; 2017 Aug; 42(6):675-676. PubMed ID: 28621002
[No Abstract] [Full Text] [Related]
3. Synergistic cytokine effects as apremilast response predictors in patients with psoriasis.
Garcet S; Nograles K; Correa da Rosa J; Schafer PH; Krueger JG
J Allergy Clin Immunol; 2018 Sep; 142(3):1010-1013.e6. PubMed ID: 29936103
[No Abstract] [Full Text] [Related]
4. Mechanisms Underlying the Clinical Effects of Apremilast for Psoriasis.
Pincelli C; Schafer PH; French LE; Augustin M; Krueger JG
J Drugs Dermatol; 2018 Aug; 17(8):835-840. PubMed ID: 30124722
[TBL] [Abstract][Full Text] [Related]
5. Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.
Ohtsuki M; Okubo Y; Komine M; Imafuku S; Day RM; Chen P; Petric R; Maroli A; Nemoto O
J Dermatol; 2017 Aug; 44(8):873-884. PubMed ID: 28391657
[TBL] [Abstract][Full Text] [Related]
6. Assessing the Risk of Apremilast Use for Psoriasis During the COVID-19 Pandemic.
Kearns DG; Uppal S; Chat VS; Wu JJ
J Drugs Dermatol; 2021 May; 20(5):582-583. PubMed ID: 33938697
[No Abstract] [Full Text] [Related]
7. Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis.
Bianchi L; Del Duca E; Romanelli M; Saraceno R; Chimenti S; Chiricozzi A
Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):1121-8. PubMed ID: 27376729
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study.
Gottlieb AB; Matheson RT; Menter A; Leonardi CL; Day RM; Hu C; Schafer PH; Krueger JG
J Drugs Dermatol; 2013 Aug; 12(8):888-97. PubMed ID: 23986162
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase 4 inhibitor apremilast improves insulin resistance in psoriasis patients.
Ikumi K; Torii K; Sagawa Y; Kanayama Y; Nakada A; Nishihara H; Morita A
J Dermatol; 2022 Apr; 49(4):e125-e126. PubMed ID: 34961971
[No Abstract] [Full Text] [Related]
10. Treating moderate plaque psoriasis: prospective 6-month chart review of patients treated with apremilast.
Knuckles MLF; Levi E; Soung J
J Dermatolog Treat; 2019 Aug; 30(5):430-434. PubMed ID: 30339049
[No Abstract] [Full Text] [Related]
11. Real-world use of apremilast for patients with psoriasis in Japan.
Kishimoto M; Komine M; Hioki T; Kamiya K; Sugai J; Ohtsuki M
J Dermatol; 2018 Nov; 45(11):1345-1348. PubMed ID: 30168880
[TBL] [Abstract][Full Text] [Related]
12. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.
Schafer PH; Parton A; Gandhi AK; Capone L; Adams M; Wu L; Bartlett JB; Loveland MA; Gilhar A; Cheung YF; Baillie GS; Houslay MD; Man HW; Muller GW; Stirling DI
Br J Pharmacol; 2010 Feb; 159(4):842-55. PubMed ID: 20050849
[TBL] [Abstract][Full Text] [Related]
13. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.
Wu JJ; Pelletier C; Ung B; Tian M
J Med Econ; 2019 Apr; 22(4):365-371. PubMed ID: 30652520
[TBL] [Abstract][Full Text] [Related]
14. Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis.
Torres T; Puig L
Am J Clin Dermatol; 2018 Feb; 19(1):23-32. PubMed ID: 28597182
[TBL] [Abstract][Full Text] [Related]
15. Chronic tearing induced by apremilast.
Norris MR; Bielory L
Ann Allergy Asthma Immunol; 2018 Sep; 121(3):375. PubMed ID: 29969663
[No Abstract] [Full Text] [Related]
16. Is apremilast for psoriasis as effective and safe as reported in clinical trials? Five-year experience from a Greek tertiary hospital: long-term real-life efficacy and safety of apremilast in Greece.
Sotiriou E; Tsentemeidou A; Vakirlis E; Sideris N; Bakirtzi K; Papadimitriou I; Lallas A; Ioannides D
Clin Exp Dermatol; 2021 Dec; 46(8):1542-1544. PubMed ID: 33811368
[TBL] [Abstract][Full Text] [Related]
17. Apremilast for the management of moderate to severe plaque psoriasis.
Vangipuram R; Alikhan A
Expert Rev Clin Pharmacol; 2017 Apr; 10(4):349-360. PubMed ID: 28276777
[TBL] [Abstract][Full Text] [Related]
18. Real-World Effectiveness and Safety of Apremilast in Older Patients with Psoriasis.
Phan C; Beneton N; Delaunay J; Reguiai Z; Boulard C; Fougerousse AC; Cinotti E; Romanelli M; Mery-Bossard L; Thomas-Beaulieu D; Parier J; Maccari F; Chaby G; Bastien M; Begon E; Samimi M; Prignano F; Beauchet A; Mahé E;
Drugs Aging; 2020 Sep; 37(9):657-663. PubMed ID: 32696432
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.
Reich K; Gooderham M; Bewley A; Green L; Soung J; Petric R; Marcsisin J; Cirulli J; Chen R; Piguet V
J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):397-402. PubMed ID: 29220542
[TBL] [Abstract][Full Text] [Related]
20. Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials.
Thaçi D; Kimball A; Foley P; Poulin Y; Levi E; Chen R; Feldman SR
J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):498-506. PubMed ID: 27538241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
